Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.51 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.44 |
| ▸ | FEN1 | P39748 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19337580 | 0.86 | TSHR (0.54) | TSHRMEN1KMT2AADRB2ADRB1 | |
| SCHEMBL29535471 | 0.84 | TSHR (0.80) | TSHRMEN1KMT2AADRB2ADRB1 | |
| SCHEMBL1569293 | 0.84 | TSHR (0.80) | TSHRMEN1KMT2AADRB2ADRB1 | |
| SCHEMBL17797782 | 0.84 | TSHR (0.66) | TSHRMEN1KMT2AADRB2ADRB1 | |
| SCHEMBL2637229 | 0.82 | TSHR (0.59) | TSHRMEN1KMT2AADRB2ADRB1 | |
| SCHEMBL7933514 | 0.82 | TSHR (0.59) | TSHRMEN1KMT2AADRB2ADRB1 | |
| SCHEMBL27501881 | 0.82 | TSHR (0.77) | TSHRMEN1KMT2AADRB2ADRB1 | |
| SCHEMBL9341422 | 0.81 | TSHR (0.57) | TSHRMEN1KMT2AADRB2ADRB1 | |
| SCHEMBL17681654 | 0.81 | TSHR (0.57) | TSHRMEN1KMT2AADRB2ADRB1 | |
| SCHEMBL4207450 | 0.81 | TSHR (0.57) | TSHRMEN1KMT2AADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107619392-A | 1H-indazole-4-ether compounds and use thereof as IDO inhibitors | 西华大学 | 2018-01-23 | — | — | CN | disclosed |
| CN-102424673-B | Montelukast sodium intermediate and method for synthesizing montelukast sodium thereof | ZHEJIANG HISUN PHARM CO LTD | 2013-12-04 | — | — | CN | disclosed |
| CN-101638381-A | Synthesis method of montelukast sodium intermediate | LUNAN PHARM GROUP CORP | 2010-02-03 | — | — | CN | disclosed |
| US-7101912-B2 | Carbidopa prodrugs and derivatives, and compositions and uses thereof | XENOPORT, INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-20040167216-A1 | Carbidopa prodrugs and derivatives, and compositions and uses thereof | XIANG JIA-NING (US) | 2004-08-26 | — | — | US | disclosed |
| WO-2004052841-A1 | CARBIDOPA PRODRUGS AND USES THEREOF | XENOPORT, INC. (US) | 2004-06-24 | — | — | WO | disclosed |
| US-6677331-B2 | HAVING SUBSTITUTED IMIDAZO(5,1-B)THIAZOLE GROUP AT 2-POSITION; MICROBIOCIDES AGAINST BETA-LACTAMASE PRODUCING BACTERIA AND RESISTANT PSEUDOMONAS | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-01-13 | — | — | US | disclosed |
| US-20030149016-A1 | Novel carbapenem derivatives | KANO YUKO (JP) | 2003-08-07 | — | — | US | disclosed |
| US-6458780-B1 | IMIDAZO(5,1-B)THIAZOLE GROUP AT THE 2-POSITION ON THE CARBAPENEM RING HAVE HIGH ANTI-MICROBIAL ACTIVITIES AGAINST .BETA.-LACTAMASE PRODUCING BACTERIA, MRSA, RESISTANT-PSEUDOMONAS AERUGINOSA, PRSP, ENTEROCOCCI, AND | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-10-01 | — | — | US | disclosed |
| EP-1101766-A1 | NOVEL CARBAPENEM DERIVATIVES | MEIJI SEIKA KAISHA LTD. (JP) | 2001-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167216-A1 | Carbidopa prodrugs and derivatives, and compositions and uses thereof | PDE3A, ADORA2A, CDA | TSHR 1846/4885MEN1 2470/4885KMT2A 1867/4885 |
| US-20030149016-A1 | Novel carbapenem derivatives | DPEP1, TMPRSS15, STK35 | TSHR 4209/4885MEN1 2832/4885KMT2A 3040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.